Lilly decided that a potential safety problem might ground the drug, and the company dropped it.

FORBES: Antibiotic Breakthroughs Fall Short

Some hope that potential safety problems with currently marketed stents won't be a problem with the Conor CoStar.

FORBES: J&J Targets Stent Maker